Structure (Image 1)
Desvenlafaxine
Product Images NDC 50090-4388
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-4388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Image 2)
This is a pharmacokinetic analysis of the impact of different intrinsic factors such as renal and hepatic impairment and population description on Desvenlafaxine. The results are shown in Figure 1 and include values for Cmax and AUC. The study involves different levels of impairment and population description such as gender and age. Not available.*
2 (Image 3)
3 (Image 4)
4 (Image 5)
This is a graph representing the estimated proportion of patients with relapse, with Desvenlafaxine 50 mg and Placebo as the two variables. The x-axis shows the time to relapse in days from randomization and the y-axis shows the percentage of patients with relapse. The graph shows that at around 50 days, the proportion of patients with relapse is around 40% for the Desvenlafaxine group and around 50% for the Placebo group. At 200 days, the percentage of patients with relapse for both groups is 0.*
5 (Image 6)
This is a graph that compares Desvenlafaxine to Placebo in terms of the percentage of patients with relapse over time in days from randomization. It shows that fewer patients experienced relapse with Desvenlafaxine compared to Placebo.*
Label Image (Lbl500904388)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
